YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 12.5
(0.16%)
HKD 12.5
(0.16%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 289.45 Million CNY | -58.14% |
| 2022 | 691.52 Million CNY | -78.01% |
| 2021 | 3.14 Billion CNY | 1556.56% |
| 2020 | 189.85 Million CNY | -93.46% |
| 2019 | 2.9 Billion CNY | 0.0% |
| 2018 | - CNY | -100.0% |
| 2017 | 10 Million CNY | -50.0% |
| 2016 | 20 Million CNY | -77.78% |
| 2015 | 90 Million CNY | -37.93% |
| 2014 | 145 Million CNY | -57.13% |
| 2013 | 338.27 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 990.78 Million CNY | 243.68% |
| 2023 Q2 | 507.08 Million CNY | -26.67% |
| 2023 Q4 | 289.45 Million CNY | -42.92% |
| 2023 FY | 289.45 Million CNY | -58.14% |
| 2022 Q2 | 661.9 Million CNY | -78.95% |
| 2022 FY | 691.52 Million CNY | -78.01% |
| 2022 Q4 | 691.52 Million CNY | 4.48% |
| 2021 Q4 | 3.14 Billion CNY | 2.36% |
| 2021 Q2 | 3.07 Billion CNY | 1518.39% |
| 2021 FY | 3.14 Billion CNY | 1556.56% |
| 2020 FY | 189.85 Million CNY | -93.46% |
| 2020 Q2 | 2.95 Billion CNY | 1.64% |
| 2020 Q4 | 189.85 Million CNY | -93.57% |
| 2019 FY | 2.9 Billion CNY | 0.0% |
| 2019 Q2 | 2.82 Billion CNY | 0.0% |
| 2019 Q4 | 2.9 Billion CNY | 2.73% |
| 2018 Q4 | - CNY | -100.0% |
| 2018 Q2 | 10 Million CNY | 0.0% |
| 2018 FY | - CNY | -100.0% |
| 2017 Q2 | 20 Million CNY | 0.0% |
| 2017 FY | 10 Million CNY | -50.0% |
| 2017 Q4 | 10 Million CNY | -50.0% |
| 2016 FY | 20 Million CNY | -77.78% |
| 2016 Q2 | 90 Million CNY | 0.0% |
| 2016 Q4 | 20 Million CNY | -77.78% |
| 2015 Q2 | 122.5 Million CNY | -15.52% |
| 2015 Q4 | 90 Million CNY | -26.53% |
| 2015 FY | 90 Million CNY | -37.93% |
| 2014 FY | 145 Million CNY | -57.13% |
| 2014 Q4 | 145 Million CNY | 0.0% |
| 2013 FY | 338.27 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -13862.911% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 70.763% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | -147.132% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | -4.798% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -309.778% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -702.766% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -2161.159% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -256.937% |
| SSY Group Limited | 1.94 Billion HKD | 85.138% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -560.847% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 51.123% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 98.258% |